Mpox Prevention Self-Efficacy and Associated Factors Among Men Who Have Sex With Men in China: Large Cross-Sectional Study.

JMIR Public Health Surveill

Public Health Research Center, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, 1111 Xianxia Road, Changning District, Shanghai, 200335, China, 86 021-52039999.

Published: February 2025

Background: Self-efficacy in mpox (formerly known as monkeypox) prevention plays a pivotal role in promoting preventive behaviors by fostering a sense of control and motivation, especially among men who have sex with men (MSM), the population most affected by mpox in many countries.

Objective: This study aims to assess the mpox prevention self-efficacy among MSM in China and identify factors influencing it, using a validated mpox prevention self-efficacy scale.

Methods: From October 2023 to March 2024, a nationwide cross-sectional study was conducted among MSM (aged ≥18 years) across 6 geographic regions in China using a snowball sampling method. The recruited participants (effective response rate=2403/2481, 96.9%) were asked to complete an anonymous questionnaire designed based on prior knowledge of mpox and social cognitive theory. The mpox prevention self-efficacy scale was evaluated for construct validity using exploratory factor analysis and confirmatory factor analysis, and its reliability was assessed using the Cronbach α coefficient. Univariate and multivariable logistic regression analyses were used to examine the factors associated with mpox prevention self-efficacy among MSM.

Results: A total of 2403 MSM participants were included, with a mean age of 29 (IQR 19-39) years. Of these, 1228 (51.1%) were aged 25-34 years, 1888 (78.6%) held a college degree or higher, and 2035 (84.7%) were unmarried. The median mpox prevention self-efficacy score was 23 (IQR 18-28). Exploratory factor analysis retained 6 items of the mpox prevention self-efficacy scale. Confirmatory factor analysis confirmed a strong model fit (χ²₅=32.1, n=1225; P<.001; comparative fit index=0.991; root mean square error of approximation=0.067; standardized root mean square residual=0.02; goodness-of-fit index=0.992; normed fit index=0.990; incremental fit index=0.991; Tucker-Lewis index=0.974), with all indices within acceptable ranges. The scale demonstrated good internal consistency, with a Cronbach α of 0.859. The positive factors associated with mpox prevention self-efficacy were mpox-related knowledge (OR 1.107, 95% CI 1.070-1.146), perceived risk awareness (OR 1.338, 95% CI 1.132-1.583), and mpox risk perception (OR 1.154, 95% CI 1.066-1.250), while the negative factor was age, with individuals aged 25 years and older exhibiting lower self-efficacy in mpox prevention (25-34 years: OR 0.789, 95% CI 0.642-0.970; 35-44 years: OR 0.572, 95% CI 0.444-0.736; 45 years and older: OR 0.569, 95% CI 0.394-0.823).

Conclusions: These findings highlight the critical role of targeted interventions to enhance mpox prevention self-efficacy, particularly through increasing knowledge, perceived risk awareness, and risk perception. Such interventions are especially important for middle-aged and older MSM, who may experience a decline in self-efficacy. Strengthening self-efficacy in these areas is essential for promoting sustained preventive behaviors, improving mental well-being, and contributing to more effective mpox prevention and control within the MSM community.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11887935PMC
http://dx.doi.org/10.2196/68400DOI Listing

Publication Analysis

Top Keywords

mpox prevention
28
prevention self-efficacy
28
factor analysis
16
mpox
10
self-efficacy
8
men sex
8
sex men
8
cross-sectional study
8
self-efficacy scale
8
exploratory factor
8

Similar Publications

The 2022 Mpox virus (MPXV) outbreak revitalized questions about immunity against MPXV and vaccinia-based vaccines (VAC-V), but studies are limited. We analyzed immunity against MPXV in individuals infected with MPXV or vaccinated with the licensed modified vaccinia Ankara (MVA) Bavarian Nordic or an experimental MVA-HIVB vaccine. The frequency of neutralizing antibody responders was higher among MPXV-infected individuals than MVA vaccinees.

View Article and Find Full Text PDF

Cases of high-consequence infectious diseases identified in the UK, 1962-2023.

J Med Microbiol

March 2025

NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, UK.

The management of patients with acute infectious diseases can present significant challenges, especially if the causative agent has a propensity for person-to-person transmission. In such cases, effective patient management is dependent on both rapid identification of disease and the provision of necessary medical care while adhering to suitable infection prevention and control measures to reduce the potential for onwards transmission. The UK has operated a defined system for managing patients with high-consequence infectious diseases (HCIDs) since the 1970s, when protocols were first implemented following the first descriptions of several viral haemorrhagic fever diseases, including Marburg virus disease, Lassa fever and Ebola virus disease (EVD).

View Article and Find Full Text PDF

Early in the 2022 mpox outbreak, the U.S. recommendation was to administer two doses of the JYNNEOS® vaccine 4 weeks apart.

View Article and Find Full Text PDF

Mapping Global Scientific Production on Human Immunodeficiency Virus and Monkeypox: A Scientometric Study.

Health Sci Rep

March 2025

Grupo de Bibliometría, Evaluación de evidencia y Revisiones Sistemáticas (BEERS), Human Medicine Career Universidad Cientifica del Sur Lima Peru.

Background And Aim: HIV attacks the immune system, leading to AIDS if untreated. Mpox, a zoonotic disease like smallpox, is less severe but poses higher risks for immuno-compromised individuals, especially those with HIV. Effective prevention and treatment are crucial.

View Article and Find Full Text PDF

Personalized immunization against Mpox Clades I and Ib: Strategies to combat the emerging epidemic.

Infect Med (Beijing)

March 2025

Department of Pharmaceutics, Shree S. K. Patel College of Pharmaceutical Education and Research, Ganpat University, Mehsana 384012, India.

Mpox, formerly known as monkeypox, is a zoonotic virus of the genus, with recent outbreaks of Clade I and Ib in Central Africa presenting a considerable global health threat. This study reviews current Mpox immunization approaches, focusing on the MVA-BN, LC16-KMB, and OrthopoxVac vaccines. MVA-BN vaccination has been successful in lowering infection risks, particularly in high-risk individuals and is widely used in the USA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!